AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells

Sarah Maenhout, Stephanie Du Four, Jurgen Corthals, Bart Neyns, Kris Thielemans, Joeri Aerts

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth. Here we investigated the effects of AZD1480 on the function of different immune cell populations in a melanoma model. When MO4 tumor-bearing mice were treated with AZD1480 we observed a strong inhibition of tumor growth as well as a prolonged survival. Moreover, a significant decrease in the percentage of myeloid-derived suppressor cells (MDSCs) was observed after treatment with AZD1480. However, AZD1480 enhanced the suppressive capacity of murine MDSCs while at the same time impairing the proliferative as well as the IFN-g secretion capacity of murine T cells. The addition of AZD1480 to co-cultures of human MDSCs and T cells does not affect the suppressive activity of MDSCs but it does reduce the IFN-g secretion and the proliferative capacity of T cells. We showed that although AZD1480 has the ability to delay the tumor growth of MO4 tumor-bearing mice, this drug has detrimental effects on several aspects of the immune system. These data indicate that systemic targeting of the JAK/STAT pathway by JAK1/2 inhibition can have divergent effects on tumor growth and anti-tumor immune responses.
Original languageEnglish
Pages (from-to)6801-6815
Number of pages15
JournalOncotarget
Volume16
Issue number5
DOIs
Publication statusPublished - 30 Aug 2014

Keywords

  • AZD1480
  • tumor
  • melanoma
  • myeloid
  • suppressor cells

Fingerprint

Dive into the research topics of 'AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells'. Together they form a unique fingerprint.

Cite this